Breaking Now: Biden's Disturbing Plan to "Reset" America
The “Great Reset” started on January 20th with the inauguration of Joe Biden. Between now and the midterms, the American economy could be reshaped forever – and renowned analyst Jeff Brown has found the “lynchpin” to the entire plan.
Go here before this message is removed.

CARA Insider Trading (Cara Therapeutics)

Insider Ownership Percentage: 5.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $2,463,291.17

Cara Therapeutics Insider Trading History Chart

Cara Therapeutics Share Price & Price History

$29.19
▲ +1.72 (6.26%)
As of 04/9/2021 01:00 AM ET
Days: 30 | 90 | 365
The government is eating your gains
One former hedge fund insider is revealing how you can “flip the script” for weekly 4-figure profits - in 24 hours or less! => Click here to get the exact details.
Continue Reading
pixel

Cara Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/22/2021Joana GoncalvesInsiderSell3,000$19.65$58,950.0030,610  
3/5/2021Derek T ChalmersCEOSell3,103$17.98$55,791.94953,614  
3/5/2021Frederique Ph.D. MenzaghiSVPSell3,358$17.98$60,376.84122,677  
3/5/2021Scott TerrillionInsiderSell3,090$17.98$55,558.2054,432  
2/25/2021Derek T ChalmersCEOSell11,729$19.33$226,721.57955,343  
2/25/2021Frederique Ph.D. MenzaghiSVPSell5,003$19.33$96,707.99117,680  
2/25/2021Scott TerrillionInsiderSell4,004$19.33$77,397.3248,436  
1/21/2021Joana GoncalvesInsiderSell2,000$20.12$40,240.0028,075  
12/30/2020Derek T ChalmersCEOSell6,078$15.30$92,993.40936,593  
12/30/2020Frederique Ph.D. MenzaghiSVPSell2,812$15.30$43,023.60109,680  
12/30/2020Scott TerrillionInsiderSell1,946$15.30$29,773.8042,436  
12/28/2020Derek T ChalmersCEOSell5,000$16.00$80,000.00947,671  
12/21/2020Joana GoncalvesInsiderSell2,000$15.00$30,000.0027,373  
12/16/2020Derek T ChalmersCEOSell5,000$14.95$74,750.00928,921  
12/10/2020Derek T ChalmersCEOSell7,500$15.29$114,675.00933,921  
11/23/2020Joana GoncalvesInsiderSell2,000$15.31$30,620.0029,373  
11/19/2020Christopher PosnerDirectorSell2,000$15.82$31,640.0011,200  
11/17/2020Derek T ChalmersCEOSell11,799$16.00$188,784.00941,421  
11/17/2020Martin VogelbaumDirectorSell6,000$16.09$96,540.0014,400  
11/10/2020Joana GoncalvesInsiderSell2,000$15.00$30,000.0031,373  
10/20/2020Joana GoncalvesInsiderSell2,000$15.00$30,000.0033,373  
9/3/2020Derek T ChalmersCEOSell3,201$16.00$51,216.00953,220  
7/1/2020Derek T ChalmersCEOSell5,000$17.11$85,550.00961,421  
6/12/2020Joana GoncalvesInsiderSell10,627$15.05$159,936.3546,000  
6/3/2020Derek T ChalmersCEOSell4,300$16.01$68,843.00970,721  
6/1/2020Derek T ChalmersCEOSell700$16.00$11,200.00970,721  
6/1/2020Jeffrey L IvesDirectorSell1,000$16.00$16,000.007,000  
5/22/2020Derek T ChalmersCEOSell371$16.00$5,936.00975,292  
5/20/2020Derek T ChalmersCEOSell1,200$16.00$19,200.00975,292  
5/12/2020Derek T ChalmersCEOSell4,929$16.00$78,864.00976,492  
5/12/2020Jeffrey L IvesDirectorSell2,500$16.00$40,000.008,500  
4/21/2020Derek T ChalmersCEOSell6,348$15.56$98,774.88987,769  
4/21/2020Frederique Ph.D. MenzaghiSVPSell12,894$15.58$200,888.52117,386  
4/21/2020Jeffrey L IvesDirectorSell2,500$16.00$40,000.008,500  
4/21/2020Scott TerrillionInsiderSell2,721$15.56$42,338.7641,103  
3/4/2020Jeffrey L IvesDirectorSell2,500$16.00$40,000.008,500  
1/2/2020Derek T ChalmersCEOSell10,000$16.05$160,500.00917,769  
1/2/2020Jeffrey L IvesDirectorSell2,500$16.13$40,325.008,500  
12/4/2019Derek T ChalmersCEOSell10,699$17.05$182,417.95918,468  
12/4/2019Mani MohindruCFOSell4,755$17.05$81,072.7522,196  
12/4/2019Scott TerrillionInsiderSell3,980$17.05$67,859.0020,749  
12/2/2019Derek T ChalmersCEOSell10,000$25.79$257,900.00918,468  
12/2/2019Jeffrey L IvesDirectorSell2,500$25.83$64,575.008,500  
11/1/2019Derek T ChalmersCEOSell5,000$20.79$103,950.00928,468  
11/1/2019Jeffrey L IvesDirectorSell2,500$20.68$51,700.008,500  
10/25/2019Frederique Ph.D. MenzaghiSVPSell4,000$19.91$79,640.0063,886  
10/18/2019Frederique Ph.D. MenzaghiSVPSell4,000$19.33$77,320.0067,886  
10/11/2019Frederique Ph.D. MenzaghiSVPSell4,000$18.70$74,800.0071,886  
10/4/2019Frederique Ph.D. MenzaghiSVPSell4,000$19.19$76,760.0075,886  
10/1/2019Derek T ChalmersCEOSell10,000$18.28$182,800.00933,468  
10/1/2019Jeffrey L IvesDirectorSell2,500$18.21$45,525.008,500  
9/3/2019Derek T ChalmersCEOSell5,000$23.26$116,300.00943,468  
9/3/2019Frederique Ph.D. MenzaghiSVPSell20,000$22.92$458,400.0079,886  
9/3/2019Jeffrey L IvesDirectorSell2,500$23.31$58,275.008,500  
8/1/2019Derek T ChalmersCEOSell10,000$23.27$232,700.00948,468  
8/1/2019Frederique Ph.D. MenzaghiSVPSell20,000$23.24$464,800.0099,886  
8/1/2019Jeffrey L IvesDirectorSell2,500$23.24$58,100.008,500  
7/17/2019Frederique Ph.D. MenzaghiInsiderSell8,996$27.50$247,390.00119,886  
7/15/2019Mani MohindruCFOSell37,431$25.00$935,775.0051,294  
7/1/2019Frederique Ph.D. MenzaghiInsiderSell20,000$21.90$438,000.00128,882  
7/1/2019Jeffrey L IvesDirectorSell2,500$21.75$54,375.008,500  
5/29/2019Derek T ChalmersCEOSell5,528$21.42$118,409.76963,996  
5/29/2019Frederique Ph.D. MenzaghiInsiderSell11,397$21.19$241,502.43160,279  
5/29/2019Mani MohindruCFOSell2,496$21.39$53,389.4416,359  
3/13/2019Frederique Ph.D. MenzaghiInsiderSell20,000$18.65$373,000.00139,582  
3/13/2019Mani MohindruCFOSell16,041$19.12$306,703.9224,067  
3/1/2019Derek T ChalmersCEOSell9,792$17.04$166,855.68943,996  
2/28/2019Frederique Ph.D. MenzaghiSVPSell1,500$17.50$26,250.00142,779  
2/25/2019Frederique Ph.D. MenzaghiSVPSell2,200$17.50$38,500.00144,279  
2/1/2019Derek T ChalmersCEOSell20,000$14.99$299,800.00953,788  
1/4/2019Derek T ChalmersCEOSell20,000$13.61$272,200.00  
12/28/2018Derek T ChalmersCEOSell15,825$12.53$198,287.25993,788  
12/28/2018Derek T ChalmersCEOSell15,825$12.53$198,287.25  
12/28/2018Frederique Ph.D. MenzaghiSVPSell4,300$12.53$53,879.00  
12/28/2018Frederique Ph.D. MenzaghiSVPSell4,300$12.53$53,879.00146,479  
12/28/2018Mani MohindruCFOSell4,500$12.55$56,475.008,026  
12/28/2018Mani MohindruCFOSell4,500$12.55$56,475.00  
12/28/2018Scott TerrillionInsiderSell3,100$12.51$38,781.006,386  
12/28/2018Scott TerrillionInsiderSell3,100$12.51$38,781.00  
11/15/2018Mani MohindruCFOSell16,042$18.50$296,777.00  
11/1/2018Derek T ChalmersCEOSell20,000$18.78$375,600.00991,392  
11/1/2018Frederique Ph.D. MenzaghiSVPSell3,000$18.77$56,310.00145,000  
10/17/2018Joseph William StaufferInsiderSell11,442$20.13$230,327.462,970  
10/17/2018Mani MohindruCFOSell16,042$20.19$323,887.9816,042  
10/1/2018Derek T ChalmersCEOSell20,000$23.79$475,800.00  
10/1/2018Frederique Ph.D. MenzaghiSVPSell3,000$23.99$71,970.00  
9/4/2018Derek T ChalmersCEOSell20,000$19.71$394,200.001,031,392  
9/4/2018Frederique Ph.D. MenzaghiSVPSell3,000$19.81$59,430.0098,000  
8/20/2018Frederique Ph.D. MenzaghiSVPSell3,000$18.89$56,670.00101,000  
7/10/2018Derek T ChalmersCEOSell20,000$20.64$412,800.001,051,392  
7/2/2018Frederique Ph.D. MenzaghiSVPSell3,000$19.00$57,000.00104,000  
6/1/2018Frederique Ph.D. MenzaghiSVPSell3,000$15.49$46,470.00107,000  
5/23/2018Frederique Ph.D. MenzaghiSVPSell9,000$15.19$136,710.00110,000  
See Full Table

SEC Filings (Institutional Ownership Changes) for Cara Therapeutics (NASDAQ:CARA)

67.01% of Cara Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Cara Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
4/8/2021Baldwin Brothers Inc. MA15,327$0.33M0.0%-6.1%0.031%
4/5/2021Woodstock Corp30,149$0.66M0.1%+62.7%0.060%
3/8/2021Dimensional Fund Advisors LP68,753$1.04M0.0%+2.5%0.138%
2/25/2021Dimensional Fund Advisors LP68,753$1.04M0.0%+2.5%0.138%
2/25/2021Hsbc Holdings PLC12,888$0.20M0.0%N/A0.026%
2/23/2021Principal Financial Group Inc.10,423$0.16M0.0%N/A0.021%
2/19/2021JPMorgan Chase & Co.98,521$1.49M0.0%-2.7%0.198%
2/17/2021Freedman Financial Associates Inc.5,400$82K0.1%N/A0.011%
2/16/2021Nuveen Asset Management LLC374,936$5.67M0.0%-33.2%0.752%
2/16/2021Captrust Financial Advisors3,000$45K0.0%+20.0%0.006%
2/16/2021Price T Rowe Associates Inc. MD2,429,235$36.75M0.0%-23.6%4.875%
2/16/2021Virginia Retirement Systems ET AL27,400$0.42M0.0%N/A0.055%
2/16/2021New York Life Investments Alternatives17,985$0.27M0.2%N/A0.036%
2/16/2021ETF Managers Group LLC434,527$6.57M0.1%-32.8%0.872%
2/16/2021Engineers Gate Manager LP27,330$0.41M0.0%+2.6%0.055%
2/16/2021Charles Schwab Investment Management Inc.279,758$4.23M0.0%+0.5%0.561%
2/13/2021American International Group Inc.23,928$0.36M0.0%-2.8%0.048%
2/12/2021Stifel Financial Corp91,692$1.39M0.0%+4.8%0.184%
2/12/2021Penserra Capital Management LLC114,205$1.73M0.0%+73.2%0.229%
2/12/2021Raymond James Financial Services Advisors Inc.11,471$0.17M0.0%-6.2%0.023%
2/12/2021The Manufacturers Life Insurance Company 25,567$0.39M0.0%+3.1%0.051%
2/12/2021Credit Suisse AG49,878$0.76M0.0%+47.1%0.100%
2/12/2021Virtus ETF Advisers LLC19,799$0.30M0.1%-3.3%0.040%
2/11/2021Northern Trust Corp526,543$7.97M0.0%-1.2%1.057%
2/11/2021Barclays PLC16,589$0.25M0.0%-25.0%0.033%
2/10/2021Rhumbline Advisers57,036$0.86M0.0%+3.9%0.114%
2/10/2021Renaissance Technologies LLC278,714$4.22M0.0%-6.8%0.559%
2/9/2021Wells Fargo & Company MN126,688$1.92M0.0%+17.4%0.254%
2/9/2021Bank of New York Mellon Corp178,248$2.70M0.0%-1.6%0.358%
2/9/2021ProShare Advisors LLC16,809$0.25M0.0%+33.4%0.034%
2/8/2021Alliancebernstein L.P.49,000$0.74M0.0%-20.6%0.098%
2/8/2021Russell Investments Group Ltd.93,162$1.41M0.0%+45.8%0.187%
2/5/2021BlackRock Inc.3,632,266$54.96M0.0%-1.7%7.289%
2/5/2021Aperio Group LLC10,014$0.15M0.0%N/A0.020%
2/5/2021SG Americas Securities LLC150,901$2.28M0.0%+13.4%0.303%
2/4/2021Cambridge Investment Research Advisors Inc.10,416$0.16M0.0%N/A0.021%
2/4/2021State of Wisconsin Investment Board58,700$0.89M0.0%-11.1%0.118%
2/3/2021State of New Jersey Common Pension Fund D153,536$2.32M0.0%+2.9%0.308%
2/1/2021Alpine Woods Capital Investors LLC57,927$0.88M0.1%+217.6%0.116%
2/1/2021Victory Capital Management Inc.38,005$0.58M0.0%-5.3%0.076%
2/1/2021Assenagon Asset Management S.A.35,359$0.54M0.0%-78.5%0.071%
1/30/2021Davy Global Fund Management Ltd17,184$0.26M0.1%N/A0.034%
1/26/2021Pinnacle Associates Ltd.373,076$5.65M0.1%-7.0%0.749%
1/25/2021Rothschild Investment Corp IL36,400$0.55M0.1%+11.0%0.073%
1/20/2021Kestra Advisory Services LLC13,823$0.21M0.0%+17.9%0.028%
1/19/2021Frontier Capital Management Co. LLC376,717$5.70M0.0%+43.1%0.756%
1/19/2021DNB Asset Management AS19,210$0.29M0.0%N/A0.039%
1/12/2021Baldwin Brothers Inc. MA16,327$0.25M0.0%-4.1%0.033%
1/6/2021Woodstock Corp18,531$0.28M0.0%N/A0.037%
12/11/2020Virtu Financial LLC13,372$0.17M0.0%N/A0.027%
11/17/2020California State Teachers Retirement System62,170$0.79M0.0%+1.6%0.125%
11/16/2020Cubist Systematic Strategies LLC69,226$0.88M0.0%+40.9%0.139%
11/16/2020Squarepoint Ops LLC31,231$0.40M0.0%N/A0.063%
11/16/2020ExodusPoint Capital Management LP21,880$0.28M0.0%+32.8%0.044%
11/13/2020Morgan Stanley47,512$0.61M0.0%-7.7%0.095%
11/13/2020Charles Schwab Investment Management Inc.278,381$3.54M0.0%-0.4%0.559%
11/13/2020First Allied Advisory Services Inc.17,567$0.22M0.0%N/A0.035%
11/13/2020UBS Asset Management Americas Inc.59,579$0.76M0.0%+70.6%0.120%
11/13/2020Virtus ETF Advisers LLC20,478$0.26M0.1%-12.0%0.041%
11/12/2020JPMorgan Chase & Co.101,245$1.25M0.0%-5.3%0.203%
11/12/2020AlphaCrest Capital Management LLC19,700$0.25M0.0%N/A0.040%
11/12/2020Arrowstreet Capital Limited Partnership33,200$0.42M0.0%N/A0.067%
11/12/2020Kestra Advisory Services LLC11,729$0.15M0.0%N/A0.024%
11/10/2020State Street Corp949,533$12.08M0.0%-5.3%2.025%
11/9/2020SG Americas Securities LLC133,094$1.69M0.0%+14.3%0.284%
11/9/2020Victory Capital Management Inc.40,126$0.51M0.0%-27.3%0.086%
11/9/2020LPL Financial LLC149,542$1.90M0.0%-1.4%0.319%
11/6/2020BlackRock Inc.3,694,949$47.02M0.0%-2.0%7.881%
11/6/2020Trexquant Investment LP15,140$0.19M0.0%N/A0.032%
11/6/2020Janney Montgomery Scott LLC11,714$0.15M0.0%-10.3%0.025%
11/6/2020Aigen Investment Management LP35,637$0.45M0.1%-54.4%0.076%
11/5/2020California Public Employees Retirement System85,400$1.09M0.0%+2.5%0.182%
11/5/2020Wells Fargo & Company MN107,890$1.37M0.0%-9.5%0.230%
11/4/2020Raymond James & Associates13,661$0.17M0.0%-5.5%0.029%
11/2/2020Alpine Woods Capital Investors LLC18,239$0.23M0.0%N/A0.039%
10/30/2020BNP Paribas Arbitrage SA9,567$0.12M0.0%+548.2%0.020%
10/30/2020WINTON GROUP Ltd22,991$0.29M0.0%-15.1%0.049%
10/29/2020DekaBank Deutsche Girozentrale16,200$0.20M0.0%N/A0.035%
10/27/2020State of New Jersey Common Pension Fund D149,238$1.90M0.0%N/A0.318%
10/23/2020Pinnacle Associates Ltd.401,154$5.11M0.1%-2.9%0.856%
10/22/2020Rothschild Investment Corp IL32,800$0.42M0.0%+6.5%0.070%
10/15/2020Campbell & CO Investment Adviser LLC13,629$0.17M0.1%N/A0.029%
10/7/2020Assenagon Asset Management S.A.164,300$2.09M0.0%N/A0.350%
9/15/2020Two Sigma Advisers LP99,400$1.70M0.0%+341.8%0.212%
9/15/2020Schonfeld Strategic Advisors LLC18,954$0.32M0.0%N/A0.040%
8/25/2020Nuveen Asset Management LLC502,723$8.60M0.0%+198.0%1.072%
8/20/2020Charles Schwab Investment Management Inc.279,590$4.78M0.0%+5.9%0.596%
8/17/2020B. Riley Wealth Management Inc.29,930$0.51M0.1%-15.0%0.064%
8/17/2020Engineers Gate Manager LP11,947$0.20M0.0%N/A0.025%
8/17/2020California State Teachers Retirement System61,182$1.05M0.0%+1.7%0.130%
8/17/2020Jacobs Levy Equity Management Inc.50,303$0.86M0.0%N/A0.107%
8/17/2020Private Advisor Group LLC1,746$30K0.0%N/A0.004%
8/14/2020Captrust Financial Advisors2,500$44K0.0%N/A0.005%
8/14/2020Pinnacle Associates Ltd.413,121$7.06M0.2%-1.2%0.881%
8/14/2020Cubist Systematic Strategies LLC49,115$0.84M0.0%+376.4%0.105%
8/14/2020PDT Partners LLC67,800$1.16M0.1%N/A0.145%
8/14/2020Bank of America Corp DE1,005,524$17.20M0.0%+11.2%2.145%
8/14/2020Stifel Financial Corp88,504$1.51M0.0%+2.7%0.189%
8/14/2020Vanguard Group Inc.2,256,468$38.59M0.0%-0.9%4.813%
8/14/2020Prosight Management LP86,965$1.49M0.6%N/A0.185%
Data available starting January 2016

See Full Table
Cara Therapeutics logo
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Read More

Today's Range

Now: $29.19
$27.02
$29.65

50 Day Range

MA: $20.11
$18.08
$27.47

52 Week Range

Now: $29.19
$12.30
$29.65

Volume

2,361,768 shs

Average Volume

857,709 shs

Market Capitalization

$1.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Who are the company insiders with the largest holdings of Cara Therapeutics?

Cara Therapeutics' top insider investors include:
  1. Derek T Chalmers (CEO)
  2. Frederique PhD Menzaghi (Insider)
  3. Frederique PhD Menzaghi (SVP)
  4. Scott Terrillion (Insider)
  5. Mani Mohindru (CFO)
  6. Joana Goncalves (Insider)
  7. Martin Vogelbaum (Director)
  8. Christopher Posner (Director)
  9. Jeffrey L Ives (Director)

Who are the major institutional investors of Cara Therapeutics?

Cara Therapeutics' top institutional investors include:
  1. Woodstock Corp — 0.06%
  2. Baldwin Brothers Inc. MA — 0.03%

Which institutional investors are selling Cara Therapeutics stock?

During the last quarter, CARA stock was sold by these institutional investors:
  1. Baldwin Brothers Inc. MA
During the previous year, company insiders that have sold Cara Therapeutics company stock include:
  1. Derek T Chalmers (CEO)
  2. Frederique PhD Menzaghi (Insider)
  3. Frederique PhD Menzaghi (SVP)
  4. Scott Terrillion (Insider)
  5. Mani Mohindru (CFO)
  6. Joana Goncalves (Insider)
  7. Martin Vogelbaum (Director)

Which institutional investors are buying Cara Therapeutics stock?

During the previous quarter, CARA stock was purchased by institutional investors including:
  1. Woodstock Corp
Breaking Now: Biden's Disturbing Plan to "Reset" America
The “Great Reset” started on January 20th with the inauguration of Joe Biden. Between now and the midterms, the American economy could be reshaped forever – and renowned analyst Jeff Brown has found the “lynchpin” to the entire plan.
Go here before this message is removed.